In vitro studies in classical pre-eclampsia-like mouse models (after Nω-nitro-L-arginine-methyl ester injection, L-NAME) confirm a lower expression of LCHAD mRNA and proteins in the liver and placenta with respect to controls; however, other models, like the ApoC3-transgenic mice (suffering of an abnormal fatty acid metabolism and hypertriglyceridemia) or a mouse model with antiphospholipid syndrome (after β2-glycoprotein-I injection), present increased LCHAD expression [39,41]. The gene discussed is APOC3; the disease is hypertriglyceridemia.